Neumora Therapeutics (NMRA) Receivables - Other (2022 - 2024)

Neumora Therapeutics has reported Receivables - Other for 3 years, with the latest figure at $1.6 million in Q2 2024.

• For the quarter ending Q2 2024, Receivables - Other changed N/A year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2024 stood at $1.6 million (changed N/A YoY), and the FY2023 full-year result was $939000.0, up 2.18% from the prior year.
• Receivables - Other for Q2 2024 stood at $1.6 million, up from $906000.0 in the prior quarter.
• The five-year high for Receivables - Other was $1.6 million in Q2 2024, with the low at $668000.0 in Q3 2023.
• Average Receivables - Other over 3 years is $1.0 million, with a median of $919000.0 recorded in 2022.
• Peak annual rise in Receivables - Other reached 2.18% in 2023, while the deepest fall reached 2.18% in 2023.
• Tracing NMRA's Receivables - Other over 3 years: stood at $919000.0 in 2022, then grew by 2.18% to $939000.0 in 2023, then jumped by 73.7% to $1.6 million in 2024.
• The last three Receivables - Other figures came in at $1.6 million (Q2 2024), $906000.0 (Q1 2024), and $939000.0 (Q4 2023), per Business Quant data.

Peer Comparison